Drug Profile
Hepatitis E vaccine recombinant - GSK/NIAID/Novavax/WRAIR
Alternative Names: GL 438Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases; Novavax
- Class Synthetic vaccines; Viral hepatitis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis E
Most Recent Events
- 20 Oct 2010 No development reported - Phase-II for Hepatitis E in Nepal (IM)
- 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
- 30 Sep 2007 Development is still active